Tdspharm

At a glance

Tdspharm filed 33 disclosures in the last 12 months, including 2 insider, 2 5% holder and 1 m&a. The most recent key filing was on Jun 24.

Revenue for 2025 was ₩27.6B, up 0.4% on 2024. Operating margin was 13.6% against 13.6% a year earlier. Debt was 27% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩16.1B and operating profit of ₩2.4B.

The 2025 annual report lists 111 employees with an average tenure of 3.1 years and average pay of ₩32.1M, #1816 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩154.8M each on average. It paid no cash dividend for 2025. 김철준 and related parties held 46.26% at year end.

From the 2025 annual report

Staff: 111 (50 men, 61 women), of whom 23 on fixed-term contracts. Total pay for the year: ₩3.6B. Directors and auditors: 4, paid ₩619.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

김철준 holds 45.91%; with 5 related parties the group holds 46.26% of common shares at year end (from 45.82% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary